Baird lowered the firm’s price target on Edwards Lifesciences to $75 from $91 and keeps an Outperform rating on the shares. The firm said the company came in line with revenue and adjusted EPS estimates, but TAVR growth was below expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
- Edwards Lifesciences backs FY23 adjusted EPS $2.50-$2.60, consensus $2.55
- Edwards Lifesciences sees Q4 adjusted EPS 60c-66c, consensus 68c
- Edwards Lifesciences reports Q3 adjusted EPS 59c, consensus 59c
- Edwards Lifesciences options imply 6.8% move in share price post-earnings